About Beacon Therapeutics
Beacon Therapeutics is a Healthcare company based in Alachua (United States) founded in 2023. Gene therapies for retinal disorders including XLRP are developed. Beacon Therapeutics has raised $365.75 million across 3 funding rounds from investors including Syncona, University of Oxford and Forbion. Its chief executive, as recorded, is David Fellows. Beacon Therapeutics offers products and services including AAV Gene Therapy and VISTA Trial. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is BEACON THERAPEUTICS LIMITED. Its competitors include Kriya Therapeutics, Rezolute and Aviceda Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Beacon Therapeutics was founded in 2023 and is based in Alachua, United States. Focus is placed on the biotechnology sector, where therapeutics for retinal disorders are developed. Gene therapy candidates such as AGTC-501 are advanced for X-linked retinitis pigmentosa, while additional pipeline programs target dry age-related macular degeneration and cone-rod dystrophy. Operations center on research and development of these treatments.
- Headquarters Alachua, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website beacontx.com
- Social LinkedIn X Facebook
- Legal Name Beacon Therapeutics Limited
- Total Equity Funding$365.75M (USD)
in 3 rounds
- Latest Funding Round$75M (USD), Series C
Jan 2026
- InvestorsSyncona
& 7 more
Products & Services of Beacon Therapeutics
Beacon Therapeutics offers a comprehensive portfolio of products and services, including AAV Gene Therapy and VISTA Trial.
Delivers functional genes to treat retinal diseases like XLRP.
Phase 2/3 trial evaluating gene therapy for X-Linked Retinitis Pigmentosa.
Funding Insights of Beacon Therapeutics
Beacon Therapeutics has successfully raised a total of $365.75M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $75 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $365.75M
- Total Rounds 3
- Last Round Series C — $75M
- First Round $120.75M
(Jun 2023)
- Investors Count 8
All 3 funding rounds of Beacon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $75M | Series C | – | Goldman Sachs | |
| Jul 2024 | $170M | Series B | – | Forbion | |
| Jun 2023 | $120.75M | Series A | – | Syncona |
8 investors in total: 8 institutional.
Investors in Beacon Therapeutics
Beacon Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, University of Oxford and Forbion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Investment management services for science ventures are provided in Oxford. | oxfordscienceenterprises.com | Oxford, United Kingdom | ||
| tcgcrossover.com | ||||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
| goldmansachs.com | ||||
| retinaldegenerationfund.org | ||||
Multiple courses and degrees across various streams are offered. | ox.ac.uk | Oxford, United Kingdom |
Investor details for Beacon Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Beacon Therapeutics
31 people are tracked at Beacon Therapeutics (21 in leadership, 10 in team).
| Name | Role | Group |
|---|---|---|
David Fellows | CEO | Leadership |
Ben Novak | Senior Director | Leadership |
Ben Rigby | Vp, Business Operations | Leadership |
Carrie Reichley | Executive Director, Clinical Operations | Leadership |
Darin Curtiss | Global Vice President Of Clinical Development At Beacon Theraeutics | Leadership |
Amy Adelman House | Vice President, Corporate Development & Communications | Leadership |
Duncan Whitaker | Svp, Head Of IP And Legal | Leadership |
Abraham Scaria | Chief Scientific Officer | Leadership |
Nadia Waheed | Chief Medical Officer | Leadership |
Azadeh Kia | Vice President Gene Therapy Research | Leadership |
Benjamin G. | Executive Director Of Strategic Sourcing & Supply Chain | Leadership |
Amy Christenson | Executive Director, Medical Affairs Lead | Leadership |
Rachael Wagner | Associate Medical Director, Clinical Development | Leadership |
Donna Burch | Executive Assistant To CEO | Leadership |
Martin Quinn | Vice President, Commercialization | Leadership |
Xuandai Nguyen | Vice President, Head Of Global Program Strategy And CEO Chief Of Staff | Leadership |
Daniel C. Chung | Chief Medical Officer | Leadership |
Ashley Simmons | Executive Medical Director, Clinical Development | Leadership |
Bryce Lay | Director Of Information Technology | Leadership |
Mark Murphy Fca | VP Of Finance | Leadership |
11 more people are available in the full profile.
Complete people profiles for Beacon Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Beacon Therapeutics
3 dated milestones of Beacon Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Beacon Therapeutics is founded.
- Funding First funding round of $120.7M.
- Funding Latest funding round, Series C, of $75.0M.
Competitors of Beacon Therapeutics
Beacon Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Kriya Therapeutics, Rezolute and Aviceda Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | ||
| avicedarx.com | 2018 | Cambridge, United States | $254.66M | Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas. |
Detailed competitors of Beacon Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Beacon Therapeutics
The website of Beacon Therapeutics (beacontx.com) receives about 7.5K visits a month.
- Monthly visits7.5K
▲ 9.4% vs previous month
Websites whose visitors overlap most with Beacon Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| spacebands.com | 100% | 8.8K | #2,593,785 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Beacon Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Beacon Therapeutics
Complete news archive for Beacon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beacon Therapeutics
Beacon Therapeutics was founded in 2023.
Beacon Therapeutics is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
David Fellows is the CEO of Beacon Therapeutics, as recorded in our data.
Beacon Therapeutics is a funded company, having raised a total of $365.75M across 3 funding rounds to date. The company's 1st funding round was a Series A of $120.75M, raised on Jun 2023.
Beacon Therapeutics was founded in 2023 and is based in Alachua, United States. Focus is placed on the biotechnology sector, where therapeutics for retinal disorders are developed. Gene therapy candidates such as AGTC-501 are advanced for X-linked retinitis pigmentosa, while additional pipeline programs target dry age-related macular degeneration and cone-rod dystrophy. Operations center on research and development of these treatments.
Beacon Therapeutics's top competitors include Rezolute, Aviceda Therapeutics and Kriya Therapeutics.
Beacon Therapeutics offers AAV Gene Therapy and VISTA Trial.
Beacon Therapeutics has 8 investors. Key investors include Syncona, University of Oxford, Forbion, Oxford Science Enterprises, and TCG Crossover.
Beacon Therapeutics operates through Beacon Therapeutics Limited.